Hilsenbeck SG - Search Results

1

p53 mutation and tamoxifen resistance in breast cancer.

Elledge RM, Lock-Lim S, Allred DC, Hilsenbeck SG, Cordner L. Elledge RM, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1995 Oct;1(10):1203-8. Clin Cancer Res. 1995. PMID: 9815913

2

A demonstration that breast cancer recurrence can be predicted by neural network analysis.

Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, McGuire WL. Ravdin PM, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1992;21(1):47-53. doi: 10.1007/BF01811963. Breast Cancer Res Treat. 1992. PMID: 1391974

3

Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients.

Knorr KL, Hilsenbeck SG, Wenger CR, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM. Knorr KL, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1992;22(3):251-62. doi: 10.1007/BF01840838. Breast Cancer Res Treat. 1992. PMID: 1391991

4

Improved methods of estimating mitotic activity in solid tumors.

Hilsenbeck SG, Allred DC. Hilsenbeck SG, et al. Hum Pathol. 1992 Jun;23(6):601-2. doi: 10.1016/0046-8177(92)90312-q. Hum Pathol. 1992. PMID: 1592380 No abstract available.

5

Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues.

McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. McGuire SE, et al. Among authors: hilsenbeck sg. Cancer Lett. 1994 Feb 28;77(1):25-32. doi: 10.1016/0304-3835(94)90343-3. Cancer Lett. 1994. PMID: 7512885

6

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Osborne CK, et al. Among authors: hilsenbeck sg. J Natl Cancer Inst. 1995 May 17;87(10):746-50. doi: 10.1093/jnci/87.10.746. J Natl Cancer Inst. 1995. PMID: 7563152

7

Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells.

Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Figueroa JA, et al. Among authors: hilsenbeck sg. J Cell Physiol. 1993 Nov;157(2):229-36. doi: 10.1002/jcp.1041570204. J Cell Physiol. 1993. PMID: 7693722

8

Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.

Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Reddy KB, et al. Among authors: hilsenbeck sg. Cell Growth Differ. 1994 Dec;5(12):1275-82. Cell Growth Differ. 1994. PMID: 7696176

9

Heat shock proteins and drug resistance.

Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Fuqua SA, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1994;32(1):67-71. doi: 10.1007/BF00666207. Breast Cancer Res Treat. 1994. PMID: 7819588 Review.

10

Rising levels of estrogen receptor in breast cancer over 2 decades.

Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM. Pujol P, et al. Among authors: hilsenbeck sg. Cancer. 1994 Sep 1;74(5):1601-6. doi: 10.1002/1097-0142(19940901)74:5<1601::aid-cncr2820740517>3.0.co;2-#. Cancer. 1994. PMID: 8062191

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

370 results

Search Page

Filters